

February 4, 2016

Company name: Terumo Corporation
Representative: Yutaro Shintaku,
President and CEO
Code No.: 4543, TSE Section 1

Revision to Full-Year Results Forecast for FY2015

Terumo Corporation today announced it revised the full-year results forecast for the year ending March 31, 2016 (FY2015).

Full-Year results forecast for FY2015 (from April 1, 2015, to March 31, 2016)

Amount unit: million JPY

	Net Sales	Operating Income	Ordinary Income	Profit Attributable to Owners of Parent	EPS (Yen)
Previous Forecast	525,000	76,000	73,000	48,500	128.73
Revised Forecast	525,000	80,000	75,000	50,000	132.59
Change in Amount	—	4,000	2,000	1,500	—
Rate of Change	—	5.3%	2.7%	3.1%	—
Results for the Previous Year	489,506	67,456	70,730	38,470	101.33

Reasons for the Revision

Net sales for the nine months ended December 31, 2015 were almost in line with the previous full-year results forecast for FY2015 announced on September 24, 2015. However, the percentage share of sales in high-margin products increased mainly in the Cardiac & Vascular Company, partly due to sales expansion of our drug-eluting stent "Ultimaster" developed in-house. In addition, continuous cost reduction and appropriate control of SG&A expenses contributed to increase of operating income. As a result, operating income for FY2015 is expected to exceed the previous forecast. Accordingly, both ordinary income and profit attributable to owners of parent are also expected to exceed the previous forecast.

Note: Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors.